Q-Line Biotech Ltd

Q-Line Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Q-Line Biotech Ltd

₹ 526 3.18%
18 Jun - close price
Company website NSE - SME: QLINE
About

Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]

Key Points

Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.

Website NSE - SM
  • Market Cap ₹ 1,227 Cr.
  • Current Price ₹ 526
  • High / Low ₹ 542 / 431
  • Stock P/E 21.7
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 22.5 %
  • ROE 25.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%

Cons

  • Debtor days have increased from 92.7 to 134 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
217 198
172 136
Operating Profit 45 62
OPM % 21% 31%
-11 2
Interest 8 11
Depreciation 3 7
Profit before tax 22 46
Tax % 71% 26%
9 34
EPS in Rs 56.13 21.14
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
183 203 314 342
149 165 239 244
Operating Profit 34 38 75 98
OPM % 18% 19% 24% 29%
2 3 -8 5
Interest 4 6 15 19
Depreciation 2 4 7 11
Profit before tax 30 31 44 73
Tax % 28% 29% 45% 23%
32 34 28 56
EPS in Rs 203.81 218.67 178.60 34.24
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 23%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 21%
TTM: 25%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 25%
Last Year: 26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 2 2 16
Reserves 126 160 188 230
74 97 166 225
51 81 99 87
Total Liabilities 252 339 455 559
23 60 92 145
CWIP 12 19 63 15
Investments 16 29 0 17
201 232 301 381
Total Assets 252 339 455 559

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
25 -24 -1 16
-26 -45 -59 -29
26 17 53 42
Net Cash Flow 25 -52 -7 29
Free Cash Flow -5 -72 -58 -19
CFO/OP 111% -39% 7% 43%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 66 47 96 134
Inventory Days 180 413 226 258
Days Payable 164 232 139 142
Cash Conversion Cycle 82 228 183 251
Working Capital Days -44 51 45 62
ROCE % 16% 25% 22%

Shareholding Pattern

Numbers in percentages

6 Recently
May 2026
67.51%
1.67%
10.14%
20.67%
No. of Shareholders 3,497

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings